Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

ICK-breast is a prospective, multicentric, non-interventional investigator-initiated trial (IIT) that aims to investigate the prognostic value of CRP kinetics in early and advanced or metastatic triple negative breast cancer (TNBC) under immune checkpoint inhibitor (ICI) therapy on pathological complete response (pCR) and event-free survival in early TNBC patients, and objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in advanced or metastatic TNBC.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Kobieta w wieku 18 lat lub starsza
  • Potwierdzony nowotwór piersi (wczesny, zaawansowany lub z przerzutami)
  • Nowotwór bez receptorów hormonalnych i bez receptora HER2
  • W grupie badawczej: dodatni wynik markerów immunologicznych (PD-L1) u pacjentek z nowotworem zaawansowanym
  • Planowana immunoterapia w połączeniu z chemioterapią
  • Podpisana świadoma zgoda na udział w badaniu

✗ Disqualifies

  • Nowotwór z receptorami hormonalnymi (ER lub PR dodatni)
  • Nowotwór z receptorem HER2 dodatnim
  • Wcześniejsze leczenie systemowe tego nowotworu (u pacjentek z rakiem wczesnym)
  • Wcześniejsza immunoterapia
  • Ciąża lub karmienie piersią
  • Zły ogólny stan zdrowia, niezdolność do chemioterapii

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
February 12, 2026
Sex
Female only

Locations (1)

Department of Women's Health

Tübingen, Germany

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.